1. Scrip
  2. >>Business
  3. >>Deals

Minimum Stada Takeover Level Reached Just In Time By Bain And Cinven

 
• By Sten Stovall

A last-minute surge in shareholder acceptances has pushed Bain and Cinven's €5.4bn takeover offer for Stada Arzneimittel over the finish line just in time.

Time
Bain And Cinven's €5.4bn Takeover Offer For Stada Just Met Its Acceptances Deadline • Source: Shutterstock

Crossing the line in the nick of time, Bain and Cinven's revised offer for Stada Arzneimittel AGmet its August 16 midnight deadline for garnering the minimum level of acceptances needed from shareholders to give the private equity firms their takeover target – at their second attempt – for €5.4bn ($6.3bn).

Nidda Healthcare, the acquiring company of Bain and Cinven, said in a statement on Aug 18 that it had received...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.